Imagine a world where understanding stock ownership isn't shrouded in complex jargon. It all boils down to this: knowing who owns what and who gets to vote on company decisions. Today, we're diving into the specifics of ADOCIA SA, a French biopharmaceutical company (Euronext Paris: FR0011184241 – ADOC), and their share and voting rights structure as of October 31st, 2025. This information is crucial for investors and anyone keeping an eye on the company's trajectory.
This announcement is made in compliance with both article L. 233-8 II of the French “Code de Commerce” (Commercial Code) and article 223-16 of the General Regulation of the French stock-market authorities, known as the Autorité des Marchés Financiers, or “AMF.” Think of these regulations as the rulebook ensuring transparency and fair play in the stock market.
ADOCIA SA, officially registered at 115, avenue Lacassagne, 69003 Lyon, France, specializes in researching and developing innovative treatments for diabetes and obesity. But before we get into their groundbreaking work, let's break down the share and voting rights numbers. Here's a snapshot:
ADOCIA SA: Shares and Voting Rights as of October 31, 2025
| Month | Date | Total Number of Outstanding Shares | Total Number of Theoretical Voting Rights (1) | Total Number of Exercisable Voting Rights (2) |
| :------ | :----------- | :--------------------------------- | :------------------------------------------ | :-------------------------------------------- |
| October | October 31st, 2025 | 18,298,423 | 20,389,198 | 20,381,093 |
Now, let's decode what these numbers actually mean.
(1) Theoretical Voting Rights: The Foundation for Ownership Thresholds
The "total number of theoretical voting rights" is the figure used to determine when a shareholder crosses significant ownership thresholds. These thresholds trigger certain reporting requirements and obligations. According to Article 223-11 of the AMF General Regulation, this number includes all shares with voting rights attached, even those where voting rights might be temporarily suspended. It's the broadest measure of potential influence. Think of it like the maximum potential voting power if everyone voted.
(2) Exercisable Voting Rights: The Real-World Voting Power
"Total number of exercisable voting rights," on the other hand, reflects the actual voting power that can be exercised at a shareholder meeting. This number excludes shares with suspended voting rights. In ADOCIA's case, this exclusion involves shares held by the company itself under a liquidity agreement. A liquidity agreement is essentially an arrangement to ensure there are always buyers and sellers for the stock, promoting a stable market. Shares held under such agreements often have their voting rights suspended. The AMF recommends providing this figure to the public for clarity, as per their recommendation on July 17, 2007. And this is the part most people miss: The difference between theoretical and exercisable rights shows how much of the voting power is actually 'live' and active.
In Simple Terms: Imagine a pie chart representing all the votes in the company. The "theoretical voting rights" represent the whole pie, while the "exercisable voting rights" represent the portion of the pie that's actually up for grabs in a vote. The difference is the slice held back for specific reasons.
About ADOCIA: Innovating in Metabolic Diseases
ADOCIA is a biopharmaceutical company dedicated to discovering and developing therapeutic solutions for metabolic diseases, with a primary focus on diabetes and obesity. They have a diverse pipeline of drug candidates built on four proprietary technology platforms:
- BioChaperone®: For developing next-generation insulins and combination hormone products.
- AdOral®: An oral peptide delivery technology, aiming to make peptide-based drugs easier to administer.
- AdoShell®: An immunoprotective biomaterial designed for cell transplantation, initially focused on pancreatic cell transplantation for diabetes.
- AdoGel®: A long-acting drug delivery platform, providing sustained release of medications.
With over 25 patent families, ADOCIA is committed to innovation in the field. Based in Lyon, France, and employing around 80 people, ADOCIA is listed on the Euronext™ Paris regulated market (Euronext: ADOC; ISIN: FR0011184241).
Now, here's a question for you: Do you think it's crucial for companies to be this transparent about their share and voting rights? And how much weight should suspended voting rights have in influencing investor decisions? Share your thoughts and start the conversation below!
